Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback